Document is current
Any future updates will be listed below
-
Authors
Kornienko, Julia https://orcid.org/0000-0002-7876-230X
RodrÃguez-MartÃnez, Marta
Fenzl, Kai https://orcid.org/0000-0001-8097-7740
Hinze, Florian
Schraivogel, Daniel
Grosch, Markus https://orcid.org/0000-0001-9016-8920
Tunaj, Brigit
Lindenhofer, Dominik https://orcid.org/0000-0001-8838-7163
Schraft, Laura https://orcid.org/0009-0005-4504-8926
Kueblbeck, Moritz
Smith, Eric https://orcid.org/0000-0002-5915-9492
Mao, Chad https://orcid.org/0000-0002-6765-5621
Brown, Emily
Owens, Anjali
Saguner, Ardan M.
Meder, Benjamin https://orcid.org/0000-0003-0741-2633
Parikh, Victoria https://orcid.org/0000-0002-5138-5559
Gotthardt, Michael https://orcid.org/0000-0003-1788-3172
Steinmetz, Lars M.
- License Information
-
More Information
Article History
Received: 1 December 2022
Accepted: 5 July 2023
First Online: 18 July 2023
Competing interests
: L.M.S. is a co-founder and shareholder of Sophia Genetics. The authors J.K., M.R.M., K.F., M.Go., and L.M.S. filed an invention disclosure describing TNPO3 and restoring nuclear localization of RBM20 variants discussed in this paper (U.S. Provisional Patent Application No. 63/452,252, status: filed: March 15, 2023). M.Go. is an advisor for River Biomedics. A.M.S. received educational grants through his institution from Abbott, Bayer Healthcare, Biosense Webster, Biotronik, Boston Scientific, BMS/Pfizer, and Medtronic; and speaker/advisory board/consulting fees from Bayer Healthcare, Biotronik, Daiichi-Sankyo, Medtronic, Novartis, Pfizer, and Stride Bio Inc. V.N.P. is a consultant and/or advisor for Lexeo Therapeutics, BioMarin, Inc, Viz.ai and Nuevocor. The remaining authors declare no competing interests.
